Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150 million would include major innovative technology development a…
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept, respectively1 The analysis also showed >=75% of p…
If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in EuropeCHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-occlusive crises, with patients on Adakveo spending fewer days…
As we continue to expand our manufacturing capacity for transformative CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy), the European Medicines Agency (EMA) recently approved two European sites for commercial manufacturing. The sites locat…
Jakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1 Study also met key secondary endpoints, significantl…
Media ReleaseEnglish (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.3 MB) …
Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD): Innovative Medicines grew sales 7% (cc, +5% USD) and core opera…
Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptomsPortfolio will be sold at zero-profit to governments in up …
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment1 In secondary analyses, improvements in lu…
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1* Optional digital companion with sensor and a…
